Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed that 2% minoxidil solution stopped hair loss and promoted new hair growth in 85% of female pattern androgenetic alopecia patients, while 2% progesterone solution achieved similar results in 71% of patients.

This pilot study found that among male androgenetic alopecia patients, 2.5 mg oral minoxidil with platelet-rich plasma led to higher patient satisfaction than 1.25 mg, though hair count improvements were not statistically significant.

This study found that topical minoxidil 5% remains the most common treatment for androgenic alopecia due to its high tolerability and patient satisfaction, but topical sildenafil 2% shows promise as an alternative, especially with positive hair thickness outcomes in certain areas.

This case study reports a good response and tolerability for a combination treatment involving high potency topical corticosteroid, minoxidil 2%, LED, and inosine pranobex in a child with alopecia areata.

This study found that an herbal drug reduced the duration of telogen effluvium more effectively than minoxidil in patients.

In this study, minoxidil 2% produced satisfactory esthetical results in about 30% of patients, but placebo-treated subjects experienced increased hair counts without a cosmetic benefit, possibly due to seasonal variations and hair classification issues.

In this study, a combination treatment of topical 2% flutamide and 5% minoxidil significantly improved hair density, hair thickness, and patient satisfaction more than 5% minoxidil alone in patients with androgenetic alopecia over six months.

This article presents a case of central serous chorioretinopathy occurring after the use of topical minoxidil solution, but reports no clinical study findings.

This study reported that combined oral finasteride and topical 5% minoxidil treatment in men with male-pattern hair loss improved hair growth by initiating anagen in pre-existing but deficient follicles, yet the growth rates remained unchanged and did not normalize hair productivity.

This study found that both 0.01% and 0.03% bimatoprost gel and 2% minoxidil gel significantly improved eyebrow density in individuals with hypotrichosis, with no significant difference between the treatments, although the highest bimatoprost concentration showed a more favorable response.

This study found that 5% azelaic acid solution and 2% minoxidil solution both significantly increased hair density and shaft diameter in women with FPHL, with no significant differences between them.

In this study, minoxidil 2% solution was more effective than tacrolimus 0.1% ointment for promoting hair regrowth in mild to moderate patchy alopecia areata.

This study found that the ENERGI-F701 solution significantly increased hair density and reduced hair shedding in women with female pattern hair loss, with fewer local skin reactions compared to Regaine® 2% minoxidil, suggesting its effectiveness and safety as a treatment option.

This study found that combining platelet-rich plasma injections with topical 2% minoxidil for three months normalized certain immunohistochemical parameters in female patients with early-stage androgenetic alopecia.

This study evaluated a new aqueous-based nanosuspension of minoxidil for treating androgenetic alopecia and reported it was as effective as the commercial product but had better safety and tolerability, potentially improving patient compliance.

This preliminary study found that combining 5% minoxidil with 2% flutamide was associated with increased hair thickness in patients with androgenetic alopecia compared to 5% minoxidil alone.

In this study, oral minoxidil (1.25 mg and 2.5 mg) and topical 5% minoxidil significantly promoted hair regrowth in men with androgenetic alopecia over six months, showing comparable efficacy across both oral and topical treatments.

This study found that a topical solution of caffeine and minoxidil 2.5% was more effective in treating androgenetic alopecia than minoxidil 2.5% alone.

Oral minoxidil significantly reduces hair shedding in women with chronic telogen effluvium.

In this study, once-daily 5% minoxidil foam and twice-daily 2% minoxidil solution both promoted hair regrowth in women with female pattern hair loss, but noninferiority of the foam was not established.

In this study, a nanoemulsion containing lavender, peppermint, and rosemary essential oils was developed and shown to promote hair growth in mice at a rate comparable to 2% topical minoxidil, suggesting a promising natural alternative due to its antioxidant and anti-inflammatory effects.

In this study, treatment with platelet-rich plasma combined with 2% minoxidil was associated with normalization of immunohistochemical markers in patients with stage I-II androgenetic alopecia, suggesting potential for long-term therapeutic effects.

In this noninferiority study, researchers found that a 0.2% caffeine-based topical liquid was not less effective than 5% minoxidil solution in improving hair growth in men with androgenetic alopecia over six months.

In this study, using a combination of topical minoxidil (2%) and isotretinoin (0.05%) gel led to complete hair regrowth in 83.3% of alopecia areata patients within six months, demonstrating effective and well-tolerated treatment results.

In this study, a nanoemulsion containing Lavender, Peppermint, and Rosemary oils significantly promoted hair growth in C57BL/6 mice, showing effects comparable to 2% minoxidil, following formula optimization and ex vivo skin permeation testing.

Once-daily 5% minoxidil foam increases hair regrowth and density in women with hair loss, but not as effectively as twice-daily 2% minoxidil solution, though it's safer and more convenient.

This study found that a topical compounded formulation may improve hair density and general appearance in male patients with androgenetic alopecia after 6 months of use.

This study highlights a treatment approach using dissolving microneedle patches containing nanomicelles formed by stevioside to enhance the therapeutic efficacy and safety of poorly soluble drugs, as depicted in the cover illustration with luxuriant hair symbolizing its potential effectiveness.